BPA
STAB

Beacon Pointe Advisors’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Beacon Pointe Advisors’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-18,494
Closed -$5K – 1081
2022
Q2 		$5K Buy
+18,494
New +$4.78K ﹤0.01% 1037

Other funds holding STAB

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Beacon Pointe Advisors's STAB Position: Q3 2022 in Review

Beacon Pointe Advisors sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q3 2022, closing a stake of 18,494 shares — an estimated $5K sold.

Beacon Pointe Advisors first reported a position in STAB in Q2 2022 and held it in 1 quarter. The position peaked at $5K in Q2 2022. 35 funds tracked by Wall St. Rank hold STAB as of Q3 2022.

  • Beacon Pointe Advisors reported no remaining Statera Biopharma, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Beacon Pointe Advisors sold 18,494 Statera Biopharma, Inc. Common Stock shares in Q3 2022, an estimated $5K.
  • Beacon Pointe Advisors first reported a position in Statera Biopharma, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Beacon Pointe Advisors's Statera Biopharma, Inc. Common Stock position peaked at $5K in Q2 2022.
  • 35 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q3 2022.

Based on Beacon Pointe Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.